Former MedImumune executive hired to grow company’s precision health
initiatives and drug discovery programs
MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/bioinformatics?src=hash" target="_blank"gt;#bioinformaticslt;/agt;–DNAnexus, Inc., the leader in biomedical informatics and data
management, today announced the appointment of David Fenstermacher, PhD,
as Vice President of Precision Medicine and Data Services. Dr.
Fenstermacher will be responsible for overseeing the company’s data
management solutions for precision health and drug discovery
applications at leading cancer centers, academic institutions,
healthcare providers, and pharmaceutical companies.
“David is recognized as one of the most esteemed biomedical
informaticians in the world, and we are proud to add him to the growing
DNAnexus team,” said Richard Daly, Chief Executive Officer of DNAnexus.
“As a former precision medicine researcher and user of the DNAnexus
Platform, David brings a deep and valuable understanding of how DNAnexus
can help solve the complex precision health and drug discovery
challenges that our customers face on a daily basis.”
Dr. Fenstermacher brings more than 30 years of research experience as a
molecular biologist and bioinformatician. During his career, he has
designed and directed the implementation of numerous biomedical
informatics distributed computing systems to support basic,
translational, and clinical research, including multi-institution
research projects. He has also designed data warehouses that integrate
patient-level clinical data and other ’omics data to support studies
focused on cancer and other human diseases.
Prior to joining DNAnexus, Dr. Fenstermacher was the Vice President of
R&D Bioinformatics at MedImmune. He also served as the Chief Research
Information Officer for Virginia Commonwealth University and was
Founding Chair of the Department of Biomedical Informatics at the H. Lee
Moffitt Cancer Center. Dr. Fenstermacher received his Bachelor of
Science from Bloomsburg University of Pennsylvania and his PhD in
molecular biology and genetics from the University of North Carolina at
Chapel Hill.
“DNAnexus has long been at the forefront of scalable genomic analysis in
this era of precision medicine, and its cloud-based technology platform
continues to unlock numerous landmark discoveries,” said Dr.
Fenstermacher. “I am thrilled to join this accomplished team and look
forward to tackling exciting opportunities in human health by making it
easier for more partners around the world to accelerate disease
diagnosis, develop more effective treatments, and improve patient
outcomes.”
About DNAnexus
DNAnexus, the leader in biomedical informatics and data management, has
created the global network for genomics and other biomedical data,
operating in 33 countries across North America, South America, Europe,
Asia, Australia, and Africa. The secure, scalable, and collaborative
DNAnexus Platform helps thousands of researchers across a spectrum of
industries – biopharmaceutical, bioagricultural, sequencing services,
clinical diagnostics, government, and research consortia – accelerate
their genomics programs. For more information on DNAnexus, please visit www.dnanexus.com
or follow the company @DNAnexus.
Contacts
Andrew Noble
415-722-2129
andrew@bioscribe.com